CRISPR Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for CRISPR Therapeutics (CRSP).

Price Target Range — 13 Quarters

Analyst Consensus — 24 Analysts

2S.Buy

11Buy

10Hold

1Sell

Consensus RatingBuy# Analysts24Avg. Consensus PT$71Upside to Avg. PT+43.3%

Rating Trend — Last 9 Months

Recent Analyst Actions

Visualizza tutte le valutazioni →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 15, 2026	UBS	Joon Lee	Initiate	Neutral	$52
Aug 31, 2026	Citizens	Silvan Turkcan	Maintained	Market Outperform	$80
Aug 31, 2026	Needham	Gil Blum	Maintained	Buy	$82
Aug 25, 2026	Citizens	Silvan Turkcan	Maintained	Market Outperform	$80
Aug 4, 2026	Citigroup	Yigal Nochomovitz	PT Raise	Buy	$82→$88
Jul 8, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	Maintained	Buy	$80
Jul 6, 2026	Citizens	Silvan Turkcan	Maintained	Market Outperform	$80
May 13, 2026	Bernstein	William Pickering	PT Raise	Market Perform	$50→$56
May 6, 2026	Citigroup	Yigal Nochomovitz	PT Raise	Buy	$80→$82
Mar 17, 2026	Piper Sandler	Edward Tenthoff	PT Raise	Overweight	$105→$110
Feb 17, 2026	Chardan Capital	Geulah Livshits	PT Raise	Buy	$74→$76
Feb 13, 2026	TD Cowen	Tyler Van Buren	PT Raise	Hold	$40→$45
Feb 13, 2026	Evercore ISI Group	Liisa Bayko	PT Raise	Outperform	$62→$74
Feb 13, 2026	Needham	Gil Blum	PT Raise	Buy	$80→$82
Jan 30, 2026	Citizens	Silvan Turkcan	PT Cut	Market Outperform	$86→$80
Dec 23, 2025	Needham	Gil Blum	Maintained	Buy	$80
Dec 23, 2025	Citizens	Silvan Tuerkcan	Maintained	Market Outperform	$86
Nov 26, 2025	Chardan Capital	Geulah Livshits	PT Cut	Buy	$82→$74
Nov 12, 2025	Citigroup	Yigal Nochomovitz	PT Cut	Buy	$87→$77
Nov 11, 2025	RBC Capital	Luca Issi	PT Raise	Sector Perform	$42→$50

Analyst Ratings News

PRO
UBS Initiates Coverage On CRISPR Therapeutics with Neutral Rating, Announces Price Target of $52

UBS analyst Joon Lee initiates coverage on CRISPR Therapeutics (NASDAQ:CRSP) with a Neutral rating and announces Price Target of $52.

Benzinga Newsdesk

PRO
Citizens Reiterates Market Outperform on CRISPR Therapeutics, Maintains $80 Price Target

Citizens analyst Silvan Turkcan reiterates CRISPR Therapeutics (NASDAQ:CRSP) with a Market Outperform and maintains $80 price target.

Benzinga Newsdesk

PRO
Needham Reiterates Buy on CRISPR Therapeutics, Maintains $82 Price Target

Needham analyst Gil Blum reiterates CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and maintains $82 price target.

Benzinga Newsdesk

PRO
Citizens Reiterates Market Outperform on CRISPR Therapeutics, Maintains $80 Price Target

Citizens analyst Silvan Turkcan reiterates CRISPR Therapeutics (NASDAQ:CRSP) with a Market Outperform and maintains $80 price target.

Benzinga Newsdesk

PRO
Citigroup Maintains Buy on CRISPR Therapeutics, Raises Price Target to $88

Citigroup analyst Yigal Nochomovitz maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and raises the price target from $82 to $88.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on CRISPR Therapeutics, Maintains $80 Price Target

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and maintains $80 price target.

Benzinga Newsdesk

CRISPR Therapeutics AG

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

CRISPR Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
UBS Initiates Coverage On CRISPR Therapeutics with Neutral Rating, Announces Price Target of $52

PRO
Citizens Reiterates Market Outperform on CRISPR Therapeutics, Maintains $80 Price Target

PRO
Needham Reiterates Buy on CRISPR Therapeutics, Maintains $82 Price Target

PRO
Citizens Reiterates Market Outperform on CRISPR Therapeutics, Maintains $80 Price Target

PRO
Citigroup Maintains Buy on CRISPR Therapeutics, Raises Price Target to $88

PRO
HC Wainwright & Co. Reiterates Buy on CRISPR Therapeutics, Maintains $80 Price Target

People Also Watch

People Also Watch

CRISPR Therapeutics AG

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

CRISPR Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROUBS Initiates Coverage On CRISPR Therapeutics with Neutral Rating, Announces Price Target of $52

PROCitizens Reiterates Market Outperform on CRISPR Therapeutics, Maintains $80 Price Target

PRONeedham Reiterates Buy on CRISPR Therapeutics, Maintains $82 Price Target

PROCitizens Reiterates Market Outperform on CRISPR Therapeutics, Maintains $80 Price Target

PROCitigroup Maintains Buy on CRISPR Therapeutics, Raises Price Target to $88

PROHC Wainwright & Co. Reiterates Buy on CRISPR Therapeutics, Maintains $80 Price Target

People Also Watch

People Also Watch

PRO
UBS Initiates Coverage On CRISPR Therapeutics with Neutral Rating, Announces Price Target of $52

PRO
Citizens Reiterates Market Outperform on CRISPR Therapeutics, Maintains $80 Price Target

PRO
Needham Reiterates Buy on CRISPR Therapeutics, Maintains $82 Price Target

PRO
Citizens Reiterates Market Outperform on CRISPR Therapeutics, Maintains $80 Price Target

PRO
Citigroup Maintains Buy on CRISPR Therapeutics, Raises Price Target to $88

PRO
HC Wainwright & Co. Reiterates Buy on CRISPR Therapeutics, Maintains $80 Price Target